Literature DB >> 30910989

Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.

Vinod Chandran1, Fatima Abji2, Anthony V Perruccio3,4, Rajiv Gandhi5, Suzanne Li6, Richard J Cook7, Dafna D Gladman8.   

Abstract

OBJECTIVES: We aimed to identify soluble biomarkers that differentiate psoriatic arthritis (PsA) from osteoarthritis (OA).
METHODS: Markers of cartilage metabolism (cartilage oligomeric matrix protein [COMP], hyaluronan), metabolic syndrome (adiponectin, adipsin, resistin, hepatocyte growth factor [HGF], insulin, leptin) and inflammation (C-reactive protein [CRP], interleukin-1β [IL-1β], IL-6, IL-8, tumour necrosis factor alpha [TNFα], monocyte chemoattractant protein-1 [MCP-1], nerve growth factor [NGF]) were compared in serum samples from 201 patients with OA, 77 patients with PsA and 76 controls. Levels across the groups were compared using the Kruskal-Wallis test. Pairwise comparisons were made with Wilcoxon rank-sum test. Multivariate logistic regression analyses were performed to identify markers that differentiate PsA from OA. Receiver operating characteristic (ROC) curves were constructed based on multivariate models. The final model was further validated in an independent set of 73 PsA and 75 OA samples using predicted probabilities calculated with coefficients of age, sex and biomarkers.
RESULTS: Levels of the following markers were significantly different across the three groups (p<0.001)-COMP, hyaluronan, resistin, HGF, insulin, leptin, CRP, IL-6, IL-8, TNFα, MCP-1, NGF. In multivariate analysis, COMP (OR 1.24, 95% CI 1.06 to 1.46), resistin (OR 1.26, 95% CI 1.07 to 1.48), MCP-1 (OR 1.10, 95% CI 0.07 to 1.48) and NGF (OR<0.001, 95% CI <0.001 to 0.25) were found to be independently associated with PsA versus OA. The area under the ROC curve (AUROC) for this model was 0.99 compared with model with only age and sex (AUROC 0.87, p<0.001). Similar results were obtained using the validation sample.
CONCLUSION: A panel of four biomarkers may distinguish PsA from OA. These results need further validation in prospective studies. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  biomarkers; osteoarthritis; psoriatic arthritis

Mesh:

Substances:

Year:  2019        PMID: 30910989     DOI: 10.1136/annrheumdis-2018-214737

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

Review 1.  Disease activity indices in psoriatic arthritis: current and evolving concepts.

Authors:  Chrysoula G Gialouri; George E Fragoulis
Journal:  Clin Rheumatol       Date:  2021-05-18       Impact factor: 2.980

2.  Predictive Value of Monocyte Chemoattractant Protein-1 in the Development of Diastolic Dysfunction in Patients with Psoriatic Arthritis.

Authors:  Iva Uravić Bursać; Tatjana Kehler; Vedrana Drvar; Emina Babarović; Vesna Pehar Pejčinović; Antonija Ružić Baršić; Viktor Peršić; Gordana Laskarin
Journal:  Dis Markers       Date:  2022-06-03       Impact factor: 3.464

Review 3.  Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes.

Authors:  Nicola Chiarelli; Marco Ritelli; Nicoletta Zoppi; Marina Colombi
Journal:  Genes (Basel)       Date:  2019-08-12       Impact factor: 4.096

4.  A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations.

Authors:  Maria V Sokolova; David Simon; Kemal Nas; Mario M Zaiss; Yubin Luo; Yi Zhao; Jürgen Rech; Georg Schett
Journal:  Arthritis Res Ther       Date:  2020-02-12       Impact factor: 5.156

5.  Proteoglycan loss in the articular cartilage is associated with severity of joint inflammation in psoriatic arthritis-a compositional magnetic resonance imaging study.

Authors:  Daniel B Abrar; Christoph Schleich; Sven Nebelung; Miriam Frenken; Tim Ullrich; Karl Ludger Radke; Gerald Antoch; Stefan Vordenbäumen; Ralph Brinks; Matthias Schneider; Benedikt Ostendorf; Philipp Sewerin
Journal:  Arthritis Res Ther       Date:  2020-05-29       Impact factor: 5.156

Review 6.  Correlation between osteoarthritis and monocyte chemotactic protein-1 expression: a meta-analysis.

Authors:  Feifei Ni; Yanchao Zhang; Xiaoxiao Peng; Jianjun Li
Journal:  J Orthop Surg Res       Date:  2020-11-10       Impact factor: 2.359

Review 7.  Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis.

Authors:  Sabrina Porta; Matilde Otero-Losada; Rodolfo A Kölliker Frers; Vanesa Cosentino; Eduardo Kerzberg; Francisco Capani
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

8.  Serum Biomarkers of Inflammation and Turnover of Joint Cartilage Can Help Differentiate Psoriatic Arthritis (PsA) Patients from Osteoarthritis (OA) Patients.

Authors:  Michał Waszczykowski; Anna Fabiś-Strobin; Igor Bednarski; Aleksandra Lesiak; Joanna Narbutt; Jarosław Fabiś
Journal:  Diagnostics (Basel)       Date:  2020-12-31

9.  Niacinamide and undenatured type II collagen modulates the inflammatory response in rats with monoiodoacetate-induced osteoarthritis.

Authors:  Kazim Sahin; Osman Kucuk; Cemal Orhan; Mehmet Tuzcu; Ali Said Durmus; Ibrahim Hanifi Ozercan; Nurhan Sahin; Vijaya Juturu
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

10.  TNF-α Activating Osteoclasts in Patients with Psoriatic Arthritis Enhances the Recruitment of Osteoclast Precursors: A Plausible Role of WNT5A-MCP-1 in Osteoclast Engagement in Psoriatic Arthritis.

Authors:  Shang-Hung Lin; Ji-Chen Ho; Sung-Chou Li; Yu-Wen Cheng; Chung-Yuan Hsu; Wen-Yi Chou; Chang-Chun Hsiao; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.